Skip to content

Clinical study of modified letrozole regimen in ovulation induction in patients with polycystic ovary syndrome

Randomized controlled trail of modified letrozole regimen in ovulation induction in patients with polycystic ovary syndrome

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071007
Enrollment
Unknown
Registered
2023-04-28
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome

Interventions

Sponsors

Ningxia Medical University General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
No minimum to 38 Years

Inclusion criteria

Inclusion criteria: 1.PCOS and infertility were diagnosed PCOS is diagnosed according to Rotterdam consensus as fulfilling at least two of the three criteria: (1) oligo-anovulation or anovulation; (2) clinical or biochemical signs of hyperandrogenism; and (3) polycystic ovarian morphology on ultrasound, as defined by at least one ovary with 12 follicles or volume 10 ml. 2.Infertility due to PCOS,amenorrhea and ovulation disorder,at least one of the fallopian tubes is unobstructed,there are indications of out-patient expulsion promotion,and no contraindication of expulsion promotion (1)To induce ovulation to guide cohabitants (2)intrauterine artificial insemination with ovulation induction 3.PCOS intended to receive CET(IVF/ICSI/PGT)for endometrial preparation with LE stimulation due to irregular menstruation and ovulation disorder 4.=38 years of age at oocyte retrieval; 5.She has not used LE/CC and other efflux stimulating drugs in the last 3 months.

Exclusion criteria

Exclusion criteria: 1.Outpatient platoon promotion and AIH patients: (1)bilateral tubal obstruction (2)marriage without normal sex life. (3)male azoospermia 2.Uterine malformations or abnormalities:double uterus,mediastinal uterus(complete or incomplete),moderate to severe uterine adhesions,etc; 3.History of unilateral or bilateral ovarian surgery; 4.History of recurrent abortion 5.Chromosomal abnormalities in one or both partners(except chromosomal polymorphism)

Design outcomes

Primary

MeasureTime frame
Dominant follicle rate(First period);Ovulation rate after trigger(First period);

Secondary

MeasureTime frame
Expulsion cycle cancellation rate(First period);ovulation rate(First period);clinical pregnancy rate(First period);Biochemical pregnancy rate(First period);Early/late abortion rate(First period);Multiple pregnancy rate(First period);OHSS rate(First period);Intimal thickness(First period);Intimal morphology(First period);LUFS rate(First period);Malformation rate(First period);Cumulative dominance number of follicles;Cumulative ovulation rate;Cumulative biochemical pregnancy rate;Cumulative clinical pregnancy rate;Cumulative early/late abortion rate;Cumulative live birth rate;Cumulative multiple pregnancy rate;Cumulative OHSS rate;Cumulative LUFS rate;Live birth rate(First period);

Countries

China

Contacts

Public ContactJunli Zhao

Ningxia Medical University General Hospital

zhaojunli6812@163.com+86 13909519609

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026